… were randomized to receive blinded maintenance erlotinib 150 mg/day (‘early erlotinib’) or
… open-label erlotinib (‘late erlotinib’); patients who progressed on erlotinib received approved …

… The effect of active maintenance therapy on disease progression when introduced
immediately after first-line platinum-doublet chemotherapy has therefore been investigated for …

… also benefit from TKI maintenance (this mainly due to the effect of erlotinib in SATURN). As
… first-line maintenance erlotinib versus erlotinib at the time of disease progression in patients …

… /IV) NSCLC, whose disease did not progress following four cycles of … maintenance therapy
with either erlotinib 150 mg/day or placebo until unacceptable toxicity or disease progression (…

… The safety profile of maintenance erlotinib was as expected and manageable. … TTP was
measured from date of first erlotinib dose until disease progression or death due to progression. …

… therapy or delayed therapy to be started at the time of disease progression. An important …
-treated patients at disease progression so as to demonstrate that early maintenance therapy is …

… Citation68 In this trial, responding patients were also permitted to continue with erlotinib or
placebo until there was disease progression or unacceptable toxicity. The trial did not achieve …

… to investigate the effectiveness of maintenance erlotinib treatment until the time of
progression, with the goal of prolonging overall survival and delaying disease progression [19]. …

… ) as part of the run-in phase of the study, were randomized to receive oral erlotinib 150
mg/day or placebo until disease progression, unacceptable toxicity, or death.[5] In addition, …

… Erlotinib in the 1st-line maintenance setting is well tolerated, and significantly improves
disease control and delays progression versus placebo across patient subgroups. …